The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Self-Supplied Tumor Oxygenation through Separated Liposomal Delivery of H2O2 and Catalase for Enhanced Radio-Immunotherapy of Cancer
Abstract
The recent years have witnessed the blooming of cancer immunotherapy, as well as their combinational use together with other existing cancer treatment techniques including radiotherapy. However, hypoxia is one of several causes of the immunosuppressive tumor microenvironment (TME). Herein, we develop an innovative strategy to relieve tumor hypoxia by delivering exogenous H 2 O 2 into tumors and the subsequent catalase-triggered H 2 O 2 decomposition. In our experiment, H 2 O 2 and catalase are separately loaded within stealthy liposomes. After intravenous (iv) preinjection of CAT@liposome, another dose of H 2 O 2 @liposome is injected 4 h later. The sustainably released H 2 O 2 could be decomposed by CAT@liposome, resulting in a long lasting effect in tumor oxygenation enhancement. As the result, the combination treatment by CAT@liposome plus H 2 O 2 @liposome offers remarkably enhanced therapeutic effects in cancer radiotherapy as observed in a mouse tumor model as well as a more clinically relevant patient-derived xenograft tumor model. Moreover, the relieved tumor hypoxia would reverse the immunosuppressive TME to favor antitumor immunities, further enhancing the combined radio-immunotherapy with cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade. This work presents a simple yet effective strategy to promote tumor oxygenation via sequential delivering catalase and exogenous H 2 O 2 into tumors using well-established liposomal carriers, showing great potential for clinical translation in radio-immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 2,526
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Liposomal Drug Delivery Systems: An Update Review
Samad, A., Sultana, Y., & Aqil, M. (2007) · Current Drug Delivery · doi:10.2174/156720107782151269 · Cited by 906
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Photoacoustic tomography and sensing in biomedicine
Li, C., & Wang, L. V. (2009) · Physics in Medicine and Biology · doi:10.1088/0031-9155/54/19/r01 · Cited by 669
Zheng, D.-W., Li, B., Li, C.-X., Fan, J.-X., Lei, Q., Li, C., Xu, Z., & Zhang, X.-Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04156 · Cited by 663
Zhu, W., Dong, Z., Fu, T., Liu, J., Chen, Q., Li, Y., Zhu, R., Xu, L., & Liu, Z. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201600676 · Cited by 588
Self-citationSong, G., Liang, C., Yi, X., Zhao, Q., Cheng, L., Yang, K., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201504617 · Cited by 587
Self-citationReynders, K., Illidge, T., Siva, S., Chang, J. Y., & De Ruysscher, D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.011 · Cited by 574
The impact of hypoxia on tumor-associated macrophages
Henze, A.-T., & Mazzone, M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84427 · Cited by 546
Lasic, D. D., Martin, F. J., Gabizon, A., Huang, S. K., & Papahadjopoulos, D. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90162-2 · Cited by 545
Chen, Q., Liang, C., Sun, X., Chen, J., Yang, Z., Zhao, H., Feng, L., & Liu, Z. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701976114 · Cited by 535
Self-citationLight‐Activated Hypoxia‐Responsive Nanocarriers for Enhanced Anticancer Therapy
Qian, C., Yu, J., Chen, Y., Hu, Q., Xiao, X., Sun, W., Wang, C., Feng, P., Shen, Q., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201505869 · Cited by 466
Self-citationLiu, Y., Liu, Y., Bu, W., Cheng, C., Zuo, C., Xiao, Q., Sun, Y., Ni, D., Zhang, C., Liu, J., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500478 · Cited by 425
Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment
Moeller, B. J., Richardson, R. A., & Dewhirst, M. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9056-0 · Cited by 415
Song, G., Chen, Y., Liang, C., Yi, X., Liu, J., Sun, X., Shen, S., Yang, K., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201602111 · Cited by 394
Self-citationHuang, C.-C., Chia, W.-T., Chung, M.-F., Lin, K.-J., Hsiao, C.-W., Jin, C., Lim, W.-H., Chen, C.-C., & Sung, H.-W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b01784 · Cited by 372
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
Finger, E. C., & Giaccia, A. J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9224-5 · Cited by 370
Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs
Kuang, Y., Balakrishnan, K., Gandhi, V., & Peng, X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2073824 · Cited by 311
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Milosevic, M., Warde, P., Ménard, C., Chung, P., Toi, A., Ishkanian, A., McLean, M., Pintilie, M., Sykes, J., Gospodarowicz, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2711 · Cited by 289
Koukourakis, M. I., Giatromanolaki, A. N., Skarlatos, J., Corti, L., Blandamura, S., Piazza, M., Gatter, K. C., & Harris, A. L. (2001) · PubMed · Cited by 271
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.021 · Cited by 243
Yi, X., Yang, K., Liang, C., Zhong, X., Ning, P., Song, G., Wang, D., Ge, C., Chen, C., Chai, Z., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201502003 · Cited by 234
Self-citationDoxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release
Luo, D., Carter, K. A., Razi, A., Geng, J., Shao, S., Giraldo, D., Sunar, U., Ortega, J., & Lovell, J. F. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.027 · Cited by 226
Gordijo, C. R., Abbasi, A. Z., Amini, M. A., Lip, H. Y., Maeda, A., Cai, P., O'Brien, P. J., DaCosta, R. S., Rauth, A. M., & Wu, X. Y. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404511 · Cited by 209
Long-term single-cell imaging of mammalian stem cells
Schroeder, T. (2011) · Nature Methods · doi:10.1038/nmeth.1577 · Cited by 171
Derer, A., Frey, B., Fietkau, R., & Gaipl, U. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1771-8 · Cited by 158
Song, X., Feng, L., Liang, C., Gao, M., Song, G., & Liu, Z. (2016) · Nano Research · doi:10.1007/s12274-016-1274-8 · Cited by 147
Self-citationPatient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
Ricci, F., Bizzaro, F., Cesca, M., Guffanti, F., Ganzinelli, M., Decio, A., Ghilardi, C., Perego, P., Fruscio, R., Buda, A. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0274 · Cited by 135
Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
Teng, F., Kong, L., Meng, X., Yang, J., & Yu, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.012 · Cited by 102
Eisenblätter, M., Ehrchen, J. M., Varga, G., Sunderkötter, C. H., Heindel, W. L., Roth, J., Bremer, C., & Wall, A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060707 · Cited by 87
Liposome encapsulated perfluorohexane enhances radiotherapy in mice without additional oxygen supply
Xu, L., Qiu, X., Zhang, Y., Cao, K., Zhao, X., Wu, J., Hu, Y., & Guo, H. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1033-3 · Cited by 35
Targeting the Tumor Microenvironment by Immunotherapy: Part 2
Leibovici, J., Itzhaki, O., Huszar, M., & Sinai, J. (2011) · Immunotherapy · doi:10.2217/imt.11.112 · Cited by 8
Abstract LB-344: Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Huang, Y., Yuan, J., Righi, E., Duda, D. G., Fukumura, D., Poznanasky, M. C., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-344 · Cited by 2
Prostate cancer hypoxia as a predictor of early biochemical and local failure after radiotherapy.
Milosevic, M., Bristow, R. G., Ménard, C. M., Chung, P. W. M., Bayley, A., McLean, M., Toi, A., Gospodarowicz, M. K., Catton, C., & Warde, P. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.7_suppl.20 · Cited by 2
Cited by
Fu, L., Wan, Y., Qi, C., He, J., Li, C., Yang, C., Xu, H., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202006892 · Cited by 820
Glucose Oxidase‐Instructed Multimodal Synergistic Cancer Therapy
Fu, L., Qi, C., Hu, Y., Lin, J., & Huang, P. (2019) · Advanced Materials · doi:10.1002/adma.201808325 · Cited by 600
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
Zhou, Y., Fan, S., Feng, L., Huang, X., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202104223 · Cited by 463
Liang, S., Deng, X., Chang, Y., Sun, C., Shao, S., Xie, Z., Xiao, X., Ma, P., Zhang, H., Cheng, Z., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01595 · Cited by 436
Metadata
- Authors
- Song, X., Xu, J., Liang, C., Chao, Y., Jin, Q., Wang, C., Chen, M., & Liu, Z.
- Venue
- Nano Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-09-24
- Volume
- 18
- Issue
- 10
- Pages
- 6360-6368
- ISSN
- 1530-6984 (ISSN-L)
- 1530-6992
- OpenAlex
- W2893436613
- Cited by
- 298
- References
- 49
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.